NCT01903330 2025-03-05
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Epitopoietic Research Corporation
Phase 2 Active not recruiting
Clinical Trials
39 trialsNCT01894061 2025-02-17
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01814813 2025-01-24
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT01149850 2024-09-19
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01837862 2024-07-05
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Northwell Health
Phase 1/2 Completed
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT02386826 2023-09-21
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01730950 2022-12-29
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02330562 2022-06-08
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
Phase 1/2 Completed
NCT01004874 2022-04-13
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
Duke University
Phase 2 Completed
NCT00879437 2021-07-21
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Baylor College of Medicine
Phase 2 Completed
NCT02743078 2021-06-02
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
RTOG Foundation, Inc.
Phase 2 Terminated
NCT01740258 2021-01-26
BBP
Duke University
Phase 2 Completed
NCT01013285 2020-09-21
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00795665 2020-05-12
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
University of California, Davis
Phase 2 Completed
NCT01498328 2020-02-17
ReACT
Celldex Therapeutics
Phase 2 Completed
NCT00337207 2020-02-07
Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
Northwestern University
Phase 2 Completed
NCT00892177 2019-10-21
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00884741 2019-07-24
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT01582152 2019-06-05
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01164189 2019-02-28
TAVAREC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT01186406 2019-02-15
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
Duke University
Phase 2 Terminated
NCT00720356 2018-10-26
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Northwestern University
Phase 2 Completed
NCT00433381 2018-09-17
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01086345 2018-07-03
Radiosurgery Plus Bevacizumab in Glioblastoma
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT01648348 2018-05-23
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00621686 2018-05-08
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00883298 2017-03-30
Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
Center for Neurosciences, Tucson
Phase 2 Completed
NCT01189240 2015-12-14
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT01113398 2015-12-10
AMG 102 and Avastin for Recurrent Malignant Glioma
Duke University
Phase 2 Completed
NCT00667394 2015-11-05
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00525525 2014-11-14
AVF4120s
University of California, San Francisco
Phase 2 Completed
NCT00352521 2014-07-22
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
Duke University
Phase 2 Completed
NCT00268359 2014-07-21
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
Duke University
Phase 2 Completed
NCT00597402 2014-05-07
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Duke University
Phase 2 Completed
NCT00979017 2014-03-19
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Duke University
Phase 2 Completed
NCT00611325 2014-03-12
Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
Duke University
Phase 2 Completed
NCT00671970 2013-05-13
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Duke University
Phase 2 Completed
NCT00735436 2013-02-11
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
Duke University
Phase 2 Terminated